C4 Therapeutics (CCCC)
NASDAQ:CCCC
CCCC Stock Chart & Stats
$2.82
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.82
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.09 - $3.82
Previous CloseN/A
Volume165.25K
Average Volume (3M)2.88M
Market Cap
$275.17M
Enterprise Value$218.95M
Total Cash (Recent Filing)$248.54M
Total Debt (Recent Filing)$59.98M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
May 13, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding97,578,180
10 Day Avg. Volume1,947,423
30 Day Avg. Volume2,884,160
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue6.09
Enterprise Value/Gross Profit6.41
Enterprise Value/Ebitda-2.02
Forecast
1Y Price Target
$14.67Price Target Upside420.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$21.62M
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformC4T's TORPEDO platform targets protein degradation rather than inhibition, a durable scientific differentiation. A modular degrader platform can generate multiple assets across indications, creating potential high-value programs and persistent R&D leverage if clinical biology and target selection remain validated.
Strategic CollaborationsPartnerships with established pharma provide long-term validation, access to development resources and potential milestone/revenue support. Such collaborations can de-risk specific programs, accelerate trials/regulatory strategy, and supply capabilities the company lacks internally over multiple years.
Balance Sheet CushionA relatively strong equity base and low leverage give C4T financial flexibility to fund multi-year clinical plans without immediate heavy debt burden. This reduces short-term liquidity pressure, enabling execution of planned trials and discovery activities while limiting bank financing dependence.
Bears Say
Sustained Cash BurnPersistent, large negative operating and free cash flows indicate ongoing cash burn that will continue until commercialization or major partnering payments. Over time this elevates financing and dilution risk, constrains strategic optionality, and forces management to prioritize capital-efficient development or further external funding.
No Recurring Revenue / UnprofitabilityThe absence of revenue and persistent operating losses mean the business lacks internal cash generation and remains dependent on financing or partners. Structurally, this delays any pathway to self-funded growth, increases vulnerability to R&D setbacks, and weakens long-term margin sustainability until products reach market.
Clinical And Execution RiskValue is concentrated in clinical success of cemsidomide and pipeline readouts; delays or negative results materially impair prospects. Multiyear trial timelines, regulatory hurdles and the need for additional data or filings create structural execution risk that can extend time to value and increase cumulative burn.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.08 and its highest was $3.82 in the past 12 months.
What is C4 Therapeutics’s market cap?
C4 Therapeutics’s market cap is $275.17M.
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 39 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.108.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 97,578,180 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 0.361%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.67 (420.21% Upside)
$14.67 (420.21% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $22.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 13.2%
Last 30 Days ▲ 13.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.15%
12-Months-Change
Fundamentals
Return on Equity
-53.83%
Trailing 12-Months
Asset Growth
6.39%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$14.67
▲(420.21% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
3.34% Insiders
9.65% Mutual Funds
37.16% Other Institutional Investors
44.02% Public Companies and
Individual Investors